Associated Papers
Unveiling a rare BRAF mutation in minimally invasive follicular thyroid carcinoma: A case report.
Lee PS et al.
Medicine, 2024
Identification of a Novel Non-V600E BRAF Mutation in Papillary Thyroid Cancer.
Capezzone M et al.
Case Reports in Endocrinology, 2024
BRAF-Driven Pancreatic Cancer: Prevalence, Molecular Features, and Therapeutic Opportunities.
Ciner AT et al.
Molecular Cancer Research : Mcr, 2023
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.
Asselta R et al.
Thoracic Cancer, 2021
High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens.
Cheng LY et al.
Scientific Reports, 2021
A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer.
Romei C et al.
International Journal of Molecular Sciences, 2021
Negative reactions of BRAF mutation-specific immunohistochemistry to non-V600E mutations of BRAF.
Seto K et al.
Pathology International, 2020
Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.
Kim YS et al.
Bmc Urology, 2018
Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract.
Lee JY et al.
Translational Oncology, 2018
The diagnostic application of RNA sequencing in patients with thyroid cancer: an analysis of 851 variants and 133 fusions in 524 genes.
Pagan M et al.
Bmc Bioinformatics, 2016
Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer.
Lee JY et al.
Oncotarget, 2015
A 3-bp Deletion VK600-1E in the BRAF Gene Detected in a Young Woman with Papillary Thyroid Carcinoma.
Dvorakova S et al.
Endocrine Pathology, 2015
Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA.
Izumchenko E et al.
Nature Communications, 2015
Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay.
Park K et al.
Oncotarget, 2015
Pathogenetic Implications of BRAF Mutation Distribution in Stage IV Melanoma Patients.
Baiter M et al.
Dermatology (basel, Switzerland), 2015
Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
Tone AA et al.
Bmc Cancer, 2014
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
MacConaill LE et al.
The Journal of Molecular Diagnostics : Jmd, 2014
The clinical response to vemurafenib in a patient with a rare BRAFV600DK601del mutation-positive melanoma.
Trudel S et al.
Bmc Cancer, 2014
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.
Brannon AR et al.
Genome Biology, 2014
Sensitive allele-specific real-time PCR test for mutations in BRAF codon V600 in skin melanoma.
Pisareva E et al.
Melanoma Research, 2014
Prevalence, tumorigenic role, and biochemical implications of rare BRAF alterations.
Barollo S et al.
Thyroid : Official Journal of the American Thyroid Association, 2014
High-throughput sequencing and copy number variation detection using formalin fixed embedded tissue in metastatic gastric cancer.
Kim S et al.
Plos One, 2014
Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice.
Heinzerling L et al.
British Journal of Cancer, 2013
Automated universal BRAF state detection within the activation segment in skin metastases by pyrosequencing-based assay U-BRAF(V600).
Skorokhod A et al.
Plos One, 2013
Identification of biomarkers to distinguish clear cell sarcoma from malignant melanoma.
Yang L et al.
Human Pathology, 2012
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.
Deshpande V et al.
Bmc Cancer, 2011
A minireview: the role of MAPK/ERK and PI3K/Akt pathways in thyroid follicular cell-derived neoplasm.
Brzezianska E et al.
Frontiers in Bioscience (landmark Edition), 2011
Recent advances in molecular diagnosis of thyroid cancer.
Legakis I et al.
Journal of Thyroid Research, 2011
Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.
Santarpia L et al.
Cancer, 2010
BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications.
Tang KT et al.
Journal of the Chinese Medical Association : Jcma, 2010
Profiling critical cancer gene mutations in clinical tumor samples.
MacConaill LE et al.
Plos One, 2009
Targeting of the BRAF gene in papillary thyroid carcinoma (review).
Li Y et al.
Oncology Reports, 2009
High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes.
Oler G et al.
Cancer, 2009
Functional characterization of the novel T599I-VKSRdel BRAF mutation in a follicular variant papillary thyroid carcinoma.
De Falco V et al.
The Journal of Clinical Endocrinology and Metabolism, 2008
Seven-year follow-up of a juvenile female with papillary thyroid carcinoma with poor outcome, BRAF mutation and loss of expression of iodine-metabolizing genes.
Oler G et al.
Arquivos Brasileiros De Endocrinologia E Metabologia, 2008
Characterization of a novel complex BRAF mutation in a follicular variant papillary thyroid carcinoma.
Barzon L et al.
European Journal of Endocrinology, 2008
BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.
Xing M
Endocrine Reviews, 2007
BRAF mutations in melanocytic lesions and papillary thyroid carcinoma samples identified using melting curve analysis of polymerase chain reaction products.
Hay R et al.
Archives of Pathology & Laboratory Medicine, 2007
Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer.
Hou P et al.
Cell Cycle (georgetown, Tex.), 2007
Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
Fugazzola L et al.
Endocrine-related Cancer, 2006
Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis.
Oler G et al.
Clinical Endocrinology, 2005